

VU Research Portal

Optimizing usage of measurable residual disease (MRD) for treatment decision making in acute myeloid leukemia

Tettero, Jesse Marc

2024

DOI (link to publisher)

[10.5463/thesis.659](https://doi.org/10.5463/thesis.659)

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Tettero, J. M. (2024). *Optimizing usage of measurable residual disease (MRD) for treatment decision making in acute myeloid leukemia*. [PhD-Thesis - Research and graduation internal, Vrije Universiteit Amsterdam]. <https://doi.org/10.5463/thesis.659>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

TABLE OF CONTENTS

Chapter I	General Introduction and Outline of the Thesis	9
Chapter II	Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party <i>HemaSphere, 2022</i>	33
Chapter III	Analytical Assay Validation for Acute Myeloid Leukemia Measurable Residual Disease Assessment by Multiparametric Flow Cytometry <i>Cytometry Part B: Clinical Cytometry, 2023</i>	59
Chapter IV	Measurable Residual Disease-guided Therapy in Intermediate-risk Acute Myeloid Leukemia Patients is a Valuable Strategy in Reducing Allogeneic Transplantation without Negatively Affecting Survival <i>Haematologica, 2023</i>	85
Chapter V	Concordance in Measurable Residual Disease Result after First and Second Induction Cycle in Acute Myeloid Leukemia: An Outcome- and Cost-analysis <i>Frontiers in Oncology, 2022</i>	99
Chapter VI	AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML <i>Cancers (Basel), 2021</i>	119
Chapter VII	Impact of Hemodilution on Flow Cytometry Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia <i>Leukemia, 2024</i>	143
Chapter VIII	Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML <i>HemaSphere, 2023</i>	165
Chapter IX	Discussion, Conclusions & Future Perspectives	189
Chapter X	Summary	209
Chapter XI	Nederlandse Samenvatting	215

Annex I	List of publications	225
Annex II	List of contributing authors	228
Annex III	PhD portfolio	232
Annex IV	Curriculum Vitae	237
Annex V	Acknowledgements	238